Plant cannabinoids : a neglected pharmacological treasure trove Raphael Mechoulam British Journal of Pharmacology, 2005, 146, 913–915 doi : 10.1038/sj.bjp.0706415 Most of the cannabinoids in Cannabis sativa L. have not been fully evaluated for their pharmacological activity. A publication in this issue presents evidence that a plant cannabinoid, D9-tetrahydro-cannabivarin is a potent antagonist of anandamide, a major endogenous cannabinoid. It seems possible that many of the non-psychoactive constituents of this plant will be of biological interest. Keywords : Anandamide; CB1 receptor antagonist; CB2 receptor antagonist; mouse vas deferens; D9 tetrahydrocannabinol; D9-tetrahydrocannabivarin; -(þ)-(R)- WIN55212 Cannabis sativa L. produces more than 60 terpeno-phenols that have not been detected [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteCannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study. Rabinak CA, Blanchette A, Zabik NL, Peters C, Marusak HA, Iadipaolo A, Elrahal F Psychopharmacology (Berl)., 2020, Mar 11. doi : 10.1007/s00213-020-05499-8. Science/Homme: Le THC peut être utile dans le trouble de stress post-traumatique (IACM 30 mars 2020) Lors d’une étude contrôlée par placebo avec 71 participants, composée de 3 groupes (25 témoins sains, 27 adultes exposés à un traumatisme sans trouble de stress post-traumatique et 19 patients souffrant d'un trouble de stress post-traumatique), de faibles doses de THC ont réduit la réactivité liée à la menace dans une certaine [...]
Lire la suiteEndocannabinoids : A Promising Impact for Traumatic Brain Injury Lesley D. Schurman and Aron H. Lichtman Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00069 The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous [...]
Lire la suiteShort- and Long-Term Effects of Cannabis on Headache and Migraine Carrie Cuttler, Alexander Spradlin, Michael J. Cleveland, and Rebecca M. Craft Journal of Pain, 2019. doi : 10.1016/j.jpain.2019.11.001 Highlights Headache and migraine ratings were reduced by nearly 50% after using cannabis Men reported larger reductions in headache after cannabis use than women Cannabis concentrates were related to larger reductions in headache than flower Evidence for tolerance to effects of cannabis on headache and migraine was detected Evidence for medication overuse headache was not detected Abstract Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to [...]
Lire la suiteImmune Responses Regulated by Cannabidiol James M. Nichols and Barbara L.F. Kaplan Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2018.0073 Abstract Introduction : Cannabidiol (CBD) as Epidiolex (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and [...]
Lire la suiteLSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814 Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]
Lire la suiteMDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre, Magí Farré, Neus Pizarro, Mitona Pujadas and Kim P. C. Kuypers Frontiers in Pharmacology, 2017, Volume 8, Article 455 Doi : 10.3389/fphar.2017.00455 Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. Typically, it is assumed that action on the 5-HT2A receptor is the mechanism underlying these psychedelic experiences. In addition, other studies have shown associations between dissociative states and biological parameters (heart rate, cortisol), which are elevated by MDMA. In order to investigate [...]
Lire la suiteCannabis consumption and the risk of psychosis Alice Mulè, Lucia Sideli, Giuseppe Colli, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray Evidence-based Psychiatric Care, 2017, 3, 25-31 Enfin, un article récent (novembre 2018) explorant la co-occurence "consommation de cannabis / troubles "psychotique"", qui plus est international (anglo-italien), et comprenant, parmi les signataires, les célèbres Robin Murray du Kings Collège londonien, et Marta Di Forti de l'Université de Palerme, qui énonce clairement l'incapacité épidémiologique à établir un lien de causalité entre "consommation de cannabis et éclosion de troubles "psychotique"" !!! : "Conclusions : The [...]
Lire la suiteA Comparative Literature Survey of Psilocybin and LSD-25 Metabolism Ian Joyce Capstone Project CHM 400 H Cal Poly Pomona, Winter 2017 | 1 - &ç Psilocybin and lysergic acid diethylamide (LSD-25) are two of the most popular and well known psychedelic drugs. Although both of the compounds are currently illegal in the United States, a renewed interest has begun in recent years to examine and analyze these drugs for therapeutic use. This review analyzes the current research pertaining to the metabolism, biochemical pathways, receptor activity, biological signaling, physiological effects and the behavioral effects associated with both of these compounds. For psychedelic compounds to [...]
Lire la suite